trending Market Intelligence /marketintelligence/en/news-insights/trending/Gz06MofwPQmPrJq6Vj_rcw2 content esgSubNav
In This List

US FDA grants orphan drug status to Organovo's NovoTissues for liver disease

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


US FDA grants orphan drug status to Organovo's NovoTissues for liver disease

The U.S. Food and Drug Administration granted Organovo Holdings Inc.'s 3D bioprinted liver treatment, NovoTissues, the orphan drug status.

The treatment is meant to treat the alpha-1 antitrypsin deficiency, a type of genetic disorder affecting the liver.

Organovo CEO Taylor Crouch said the company was on track for filing an investigational new drug application for the treatment in 2020 as it continues to conduct safety and dosing investigations in small animal disease models.